Patents by Inventor Gordon D. Powers

Gordon D. Powers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PROTEINS COMPRISING DELTA-LIKE LIGAND 3 (DLL3) ANTIGEN BINDING DOMAINS AND THEIR USES
    Publication number: 20240025992
    Abstract: Antibodies and antigen binding regions that bind delta-like protein 3 (DLL3) are described. Multispecific antigen-binding constructs, such as bispecific antibodies, containing the antigen-binding regions that bind to DLL3 are also described. The application also describes methods of treatment or detection using the anti-DLL3 antibodies, antigen-binding fragments or multispecific antigen-binding constructs thereof, and related molecules, compositions and methods.
    Type: Application
    Filed: October 21, 2021
    Publication date: January 25, 2024
    Inventors: Danlin YANG, Sanjaya SINGH, Scott R. BRODEUR, Jill M. CARTON, Rajkumar GANESAN, Jennifer HERTZOG, Theresa MCDEVITT, Kristen M. PICHA, Ryan M. SMITH, Adam ZWOLAK, Sathyadevi VENKATARAMANI, Gordon D. POWERS
  • Anti-BCMA antibodies and uses thereof
    Patent number: 10072088
    Abstract: Provided herein are antibodies that immunospecifically bind to BCMA. Also described are related polynucleotides capable of encoding the provided BCMA-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor BCMA-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with BCMA-expressing cancer and thus may be amenable to treatment with a BCMA-specific anti-cancer therapeutic, such as the multispecific antibodies against BCMA and CD3 described herein.
    Type: Grant
    Filed: August 16, 2016
    Date of Patent: September 11, 2018
    Assignee: Janssen Pharmaceutica, NV
    Inventors: Kodandaram Pillarisetti, Eric Thomas Baldwin, Gordon D. Powers, Rosa Maria Fernandes Cardoso, Ricardo Attar, Francois Gaudet
  • Anti-BCMA Antibodies, Bispecific Antigen Binding Molecules that Bind BCMA and CD3, and Uses Thereof
    Publication number: 20170051068
    Abstract: Provided herein are antibodies that immunospecifically bind to BCMA. Also described are related polynucleotides capable of encoding the provided BCMA-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor BCMA-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with BCMA-expressing cancer and thus may be amenable to treatment with a BCMA-specific anti-cancer therapeutic, such as the multispecific antibodies against BCMA and CD3 described herein.
    Type: Application
    Filed: August 16, 2016
    Publication date: February 23, 2017
    Applicant: Janssen Pharmaceutica NV
    Inventors: Kodandaram Pillarisetti, Eric Thomas Baldwin, Gordon D. Powers, Rosa Maria Fernandes Cardoso, Ricardo Attar, Francois Gaudet
  • Bacterial RNase P proteins and their use in identifying antibacterial compounds
    Patent number: 6936432
    Abstract: The invention features novel RNase P molecules and nucleic acids encoding the same. Methods for discovery of antimicrobial compounds are also featured.
    Type: Grant
    Filed: March 1, 2001
    Date of Patent: August 30, 2005
    Assignee: Message Pharmaceuticals
    Inventors: Venkat Gopalan, Milan Jovanovic, Paul S. Eder, Tony Giordano, Gordon D. Powers, K. Asish Xavier
  • NOVEL BACTERIAL RNASE P PROTEINS AND THEIR USE IN IDENTIFYING ANTIBACTERIAL COMPOUNDS
    Publication number: 20040127480
    Abstract: The invention features novel RNase P molecules and nucleic acids encoding the same. Methods for discovery of antimicrobial compounds are also featured.
    Type: Application
    Filed: March 1, 2001
    Publication date: July 1, 2004
    Inventors: Venkat Gopalan, Milan Jovanovic, Paul S. Eder, Tony Giordano, Gordon D. Powers, K. Asish Xavier
  • Functional genomic screen for post-transcriptional 5? and 3? regulatory elements
    Patent number: 6448007
    Abstract: The invention features cDNA libraries consisting essentially of cDNA sequences that correspond to different mRNA untranslated region (UTR) sequences separate from adjacent mRNA coding sequences. The invention also features methods for generating these libraries and for identifying a regulatory UTR sequence.
    Type: Grant
    Filed: June 23, 2000
    Date of Patent: September 10, 2002
    Assignee: Message Pharmaceuticals
    Inventors: Tony Giordano, Gordon D. Powers, Paul S. Eder, Bonnie-Ann Burnett, Gretchen L. Temeles